Literature DB >> 2882987

Flavin-containing monooxygenase activity in human liver microsomes.

M E McManus, I Stupans, W Burgess, J A Koenig, P M Hall, D J Birkett.   

Abstract

Human liver microsomal flavin-containing monooxygenase activity has been studied using dimethylaniline N-oxidation and thiobenzamide S-oxidation. Except for one subject, the capacity of human liver microsomes to mediate these reactions were markedly increased at pH 8.4 compared to pH 7.4. The mean dimethylaniline N-oxidase activities at pH 7.4 and 8.4 in the four subjects tested were 2.49 +/- 1.13 and 6.59 +/- 4.04 nmol mg-1 min-1, respectively (mean +/- SD, N = 4). The mean thiobenzamide S-oxidase activities at pH 7.4 and 8.4 were 1.39 +/- 0.51 and 2.74 +/- 1.28 nmol mg-1 min-1, respectively. At pH 7.4, an antibody to the human liver NADPH-cytochrome P-450 reductase inhibited dimethylaniline N-oxidation between 4 and 38%. The same antibody had no effect on this reaction at pH 8.4. Except for one subject, a battery of cytochrome P-450 inhibitors also had little effect on this reaction. Further, preincubating human microsomes at 45 degrees C in the absence of NADPH for 4 min destroyed approximately 90% of the dimethylaniline N-oxidase activity. These data collectively suggested that the flavin-containing mono-oxygenase is the major enzyme mediating this reaction in human liver microsomes. In contrast to dimethylaniline N-oxidation, thiobenzamide S-oxidation was significantly inhibited by the anti-reductase at both pH 7.4 and 8.4, respectively. These data indicate that cytochromes P-450 contribute significantly to this reaction in human liver microsomes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2882987

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Molecular cloning of the flavin-containing monooxygenase (form II) cDNA from adult human liver.

Authors:  N Lomri; Q Gu; J R Cashman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

2.  Fleroxacin pharmacokinetics in patients with liver cirrhosis.

Authors:  R A Blouin; B A Hamelin; D A Smith; T S Foster; W J John; H A Welker
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

3.  Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes.

Authors:  H C Rawden; G O Kokwaro; S A Ward; G Edwards
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

Review 4.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

5.  Influence of rifampin on fleroxacin pharmacokinetics.

Authors:  J Schrenzel; P Dayer; T Leemann; E Weidekamm; R Portmann; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

6.  Characterisation of theophylline metabolism in human liver microsomes.

Authors:  R A Robson; A P Matthews; J O Miners; M E McManus; U A Meyer; P M Hall; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.